Strategic alliances an important factor in the search for effective DMD drugs, says analyst

21 March 2018
globaldata-logo-big

Although there have been some new drugs approved for the treatment of Duchenne muscular dystrophy (DMD) in the past year or two, none are seen as being particularly effective therapy.

These include Exondys 51 (eteplirsen) injection, from US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) and Emflaza (deflazacort) from Marathon Pharmaceuticals.

However, recent years have witnessed an increase in deal activity that may lead to future treatments, according to analytics company GlobalData.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical